CYDY - CytoDyn updates on leronlimab-treated COVID-19 patient

Late March, CytoDyn ([[CYDY]] +24.5%) announced that the Philippines FDA approved the use of Vyrologix (leronlimab) to treat a COVID-19 patient under compassionate special permit.38 hours after the subcutaneous injection of leronlimab, the patient has ‘significantly’ improved, the company announced today.The patient failed to improve despite being under high flow oxygen for 10 days with multiple doses of dexamethasone and then tocilizumab.Having been removed from high-flow oxygen, the patient was breathing on his own and had been discharged from the hospital on April 3, CytoDyn said in a statement.A webcast is scheduled for tomorrow at 4.00 PM EST to provide the investors with a full clinical update on the company pipeline including the experimental therapies targeting COVID-19 and NASH.

For further details see:

CytoDyn updates on leronlimab-treated COVID-19 patient